Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1613 1654 1675
This examiner grants 80% of resolved cases
Jeanette M. Lieb is an examiner in Tech Center 1600 and Art Unit 1613. She has 810 resolved cases. The allowance rate for these cases is 79.9 percent. This percentage represents the frequency of patent grants among her resolved matters. The interview lift is 17.2 percent. This metric measures the increase in the probability of allowance following an examiner interview. The median time to allowance is 971 days.
With 810 resolved cases, the 79.9 percent allowance rate offers a clear view of the examiner's tendencies. The 17.2 percent interview lift indicates that direct communication is an effective strategy for applicants. The 971 days median time to allowance is a key figure for planning the lifecycle of an application. These statistics help practitioners navigate the specific requirements of Art Unit 1613. The allowance rate and interview lift are the primary indicators of success in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17926479 | METHODS FOR TREATING PLASMA PROTEIN IMBALANCES OR DEPLETION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 19329431 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | Non-Final OA | Ohio State Innovation Foundation |
| 18458232 | INSECTICIDAL PROTEINS AND METHODS FOR THEIR USE | Non-Final OA | PIONEER HI-BRED INTERNATIONAL, INC. |
| 18604346 | SYSTEMS, COMPOSITIONS AND METHODS FOR TREATING DIABETES | Non-Final OA | Vanderbilt University |
| 18153872 | TANDEM REPEAT PROTEIN SEQUENCES IN PROTEIN-LIKE POLYMERS AND USES THEREOF | Non-Final OA | Northwestern University |
| 18573517 | COMBINATION COMPOSITIONS FOR THE TREATMENT OF PATHOGEN INFECTIONS AND ASSOCIATED COMPLICATIONS | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18281927 | GALECTIN-1 IMMUNOMODULATION AND MYOGENIC IMPROVEMENTS IN MUSCLE DISEASES AND AUTOIMMUNE DISORDERS | Non-Final OA | BRIGHAM YOUNG UNIVERSITY |
| 17995901 | Compositions and Methods for the Treatment of Protein Aggregation Disorders | Non-Final OA | SOLA BIOSCIENCES LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy